• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Republica Press

Your Business & Political News Source

REPUBLICA PRESS
Your Business & Political News Source

  • Home
  • BUSINESS
  • MONEY
  • POLITICS
  • REAL ESTATE
  • SCIENCE/TECH
  • US
  • WORLD

Moncef Slaoui, the former head of Operation Warp Speed, was fired from a biotech company after sexual misconduct allegations.

by

GlaxoSmithKline, the pharmaceutical company, said on Wednesday that it had fired Moncef Slaoui, the former head of Operation Warp Speed, from his position as chairman of Galvani Bioelectronics because of allegations of sexual harassment and inappropriate conduct.

The company cited allegations made by a female employee regarding incidents that occurred at GSK several years ago. The decision to terminate Dr. Slaoui is effective immediately, GSK said in a statement. GSK is the majority shareholder in Galvani Bioelectronics, a medical research company that is a joint venture with Verily Life Sciences.

Dr. Slaoui could not be reached for comment.

GSK said it had received a letter accusing Dr. Slaoui, 61, of sexual harassment and had asked a law firm to investigate. The investigation confirmed the allegations, GSK said, adding that the investigation is continuing.

Emma Walmsley, chief executive of GSK, sent a letter to employees on Wednesday saying the company had learned of the allegations in February. Neither she nor the GSK board provided details of the allegations.

Dr. Slaoui came to Operation Warp Speed from GSK, where he was in charge of developing vaccines. He headed the Trump administration’s vaccine acceleration efforts from May until January.

He drew criticism for owning stock in Moderna, maker of a coronavirus vaccine, and in GSK, which was pursuing a vaccine with Sanofi. The federal government invested $2.1 billion in the latter effort.

Dr. Slaoui eventually agreed to give up his stock in Moderna but not in GSK. To sidestep ethics regulations that would have prohibited him from owning that stock, the Trump administration designated him as a contractor.

After leaving the administration, Dr. Slaoui joined a new company, Centessa Pharmaceuticals, made up of ten biotech companies with $250 million from investors, as chief scientific officer.

View Source

Filed Under: WORLD Tagged With: Appointments and Executive Changes, Coronavirus, GlaxoSmithKline PLC, Government, internal-essential, Leadership, Privacy, Research, Sexual harassment, Slaoui, Moncef M, Trump administration

Primary Sidebar

More to See

Kohl’s ends sale talks with Franchise Group, lowers outlook

Kohl's announced Friday that it is terminating talks to sell its business, saying that retail environment has significantly deteriorated since the … [Read More...] about Kohl’s ends sale talks with Franchise Group, lowers outlook

KB Home Announces the Grand Opening of Alder Brook, a New-Home Community in Highly Desirable Enumclaw, Washington

ENUMCLAW, Wash.--(BUSINESS WIRE)--KB Home (NYSE: KBH) today announced the grand opening of Alder Brook, a new single-family home community in the … [Read More...] about KB Home Announces the Grand Opening of Alder Brook, a New-Home Community in Highly Desirable Enumclaw, Washington

$5.8M Sunset Rock Is a Massachusetts Mansion You Can’t Miss

On the market for $5,795,000, a sumptuous oceanfront home in Beverly, MA, features gardens designed by legendary landscape architect Frederick Law … [Read More...] about $5.8M Sunset Rock Is a Massachusetts Mansion You Can’t Miss

Copyright © 2022 · Republica Press · Log in · As an Amazon Associate we earn from qualifying purchases.

Terms and Conditions - Privacy Policy